Back to Rafferty Asset Management, LLC Rafferty Asset Management, LLC

BBIOBBIO

Showing 8 of 27 quarters

Position history for Rafferty Asset Management, LLCRafferty Asset Management, LLC's holdings in BridgeBio Pharma, Inc.

Yes. Rafferty Asset Management holds 40,953 shares of BBIO (BridgeBio Pharma), worth $3.1M, as of its Q2 2026 13F filing. It reduced the position by 22,227 shares (-35.2%) from Q1 2026. Rafferty Asset Management has held BBIO since Q2 2020, across 25 quarterly 13F filings.

Current Value

$3.1M

Current Shares

40,953

Total Value Change

-$3.1M

Total Shares Change

-202,378

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
40,953
-35.2%
$3.1M0.0%$74.48
0
2026-Q1
Decreased
63,180
-21.0%
$4.7M0.0%$74.26
0
2025-Q4
Decreased
80,018
-47.4%
$6.1M0.0%$76.49
0
2025-Q3
Decreased
151,990
-22.8%
$7.9M0.0%$51.94
0
2025-Q2
Decreased
196,782
-2.6%
$8.5M0.0%$43.18
0
2025-Q1
Decreased
202,128
-19.2%
$7M0.0%$34.57
0
2024-Q4
Increased
250,242
+2.8%
$6.9M0.0%$27.44
28
2024-Q3
Decreased
243,331
-10.4%
$6.2M0.0%$25.46
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used